HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Brands' Business Is Exclusively OTC Drugs As It Completes House Cleaning

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

Prestige Brands has $69m deal to divest its household cleaning business, its final non-OTC assets.. The firm will keep its “power core” OTC brands including Monistat, Summer’s Eve and Goody’s as its marketing focus.

You may also be interested in...



Summer’s Eve Line Leads Prestige Brands' Growth On Former Fleet Products

Market-leading feminine cleansing and douche brand and other products added in Prestige Brands' 2017 acquisition of CB Fleet helped drive its North American OTC health care revenues up 6.6% to $212.1m in its fiscal 2018 fourth quarter. Full-year revenues for the division in North America grew 20.5% to $868.9m fueled by the addition of the Fleet business and consumption growth in the firm’s core OTC brands, Prestige Brands said.

Prestige Brands Acquires C.B. Fleet, Boosts Women’s OTC Platform

Prestige Brands makes the deal three weeks after divesting the slower-selling Massengill douche brand and as it makes a top marketing priority of growing sales of its Monistat yeast treatment line.

Moberg Adds DermoPlast Line With Bondholders' Blessing For More

Moberg says sales of DermoPlast sprays were $12m in the 12 months through September and its purchase price is around 8.9 times the estimated EBITDA for the brand during the period.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS122676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel